Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
IART

Integra LifeSciences Holdings Corp

IART

41.27USD-0.04 (-0.10%)Market Closed
Watchlist

Market Summary

USD41.27-0.04
Market Closed
-0.10%

IART Alerts

  • Big fall in earnings (Y/Y)

IART Stock Price

View Fullscreen

IART RSI Chart

IART Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

32.61

Price/Sales (Trailing)

2.13

EV/EBITDA

18.06

Price/Free Cashflow

29.97

IART Price/Sales (Trailing)

IART Profitability

EBT Margin

7.55%

Return on Equity

6.39%

Return on Assets

2.7%

Free Cashflow Yield

3.34%

IART Fundamentals

IART Revenue

Revenue (TTM)

1.5B

Revenue Y/Y

-0.72%

Revenue Q/Q

0.3%

IART Earnings

Earnings (TTM)

100.9M

Earnings Y/Y

-60.94%

Earnings Q/Q

365.99%

Price Action

Last 7 days

0.6%

Last 30 days

10.2%

Last 90 days

6.5%

Trailing 12 Months

-27.0%

How does IART drawdown profile look like?

IART Financial Health

Current Ratio

2.89

IART Investor Care

Buy Backs (1Y)

4.04%

Diluted EPS (TTM)

1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.6B1.5B1.5B0
20221.6B1.6B1.6B1.6B
20211.4B1.5B1.5B1.5B
20201.5B1.4B1.4B1.4B
20191.5B1.5B1.5B1.5B
20181.3B1.4B1.5B1.5B
20171.0B1.0B1.1B1.2B
2016917.0M953.6M977.6M992.1M
2015816.2M831.8M860.6M882.7M
2014822.6M814.1M798.4M796.7M
2013831.3M826.7M829.9M836.2M
2012795.2M812.1M820.0M830.9M
2011740.4M755.1M770.7M780.1M
2010694.2M707.1M721.5M732.1M
2009661.6M668.5M675.5M682.5M
2008000654.6M

Latest Insider Trading transactions for IART

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 01, 2023
de witte jan
acquired
-
-
9,814
president & ceo
Nov 01, 2023
de witte jan
sold (taxes)
-157,055
36.85
-4,262
president & ceo
Sep 01, 2023
veillon-berteloot chantal
acquired
-
-
14,033
evp & chro
Aug 09, 2023
mosebrook jeffrey
sold
-52,329
44.46
-1,177
svp, fin & pao
Jul 03, 2023
mosebrook jeffrey
acquired
-
-
12,196
svp, fin & pao
Jul 03, 2023
knight lea daniels
acquired
-
-
24,391
evp & cfo
Jun 01, 2023
de witte jan
bought
299,986
38.4992
7,792
president & ceo
Jun 01, 2023
schwartz eric
bought
100,035
37.8921
2,640
evp, chief legal officer & sec
May 13, 2023
bradley keith
sold (taxes)
-9,074
49.05
-185
-
May 12, 2023
essig stuart
acquired
-
-
5,505
-

1–10 of 50

Which funds bought or sold IART recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
reduced
-28.22
-3,475,340
6,944,200
-%
Nov 30, 2023
Neo Ivy Capital Management
new
-
12,000
12,000
-%
Nov 24, 2023
DEUTSCHE BANK AG\
added
538
893,442
1,074,740
-%
Nov 22, 2023
Graham Capital Management, L.P.
sold off
-100
-991,438
-
-%
Nov 21, 2023
COMERICA BANK
reduced
-99.41
2,736
2,736
-%
Nov 21, 2023
COMERICA BANK
added
272
2,887,690
2,892,690
0.01%
Nov 21, 2023
Walleye Capital LLC
added
54.77
165,127
542,947
-%
Nov 17, 2023
JACOBS LEVY EQUITY MANAGEMENT, INC
new
-
633,343
633,343
-%
Nov 17, 2023
Diversified Trust Co
reduced
-30.93
-323,508
578,349
0.02%
Nov 16, 2023
Creative Planning
new
-
4,010
4,010
-%

1–10 of 36

Latest Funds Activity

Are funds buying IART calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IART
No. of Funds

Schedule 13G FIlings of Integra LifeSciences Holdings Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
tru st partnership, l.p.
10.20%
8,515,930
SC 13G/A
Feb 13, 2023
champlain investment partners, llc
6.30%
5,259,524
SC 13G/A
Feb 09, 2023
morgan stanley
6.8%
5,681,483
SC 13G/A
Feb 09, 2023
vanguard group inc
8.56%
7,147,759
SC 13G/A
Feb 06, 2023
wellington management group llp
6.84%
5,709,663
SC 13G/A
Feb 03, 2023
blackrock inc.
8.6%
7,143,236
SC 13G/A
Jul 08, 2022
capital research global investors
4.7%
3,869,770
SC 13G/A
Feb 14, 2022
tru st partnership, l.p.
10.32%
8,740,930
SC 13G/A
Feb 11, 2022
champlain investment partners, llc
6.72%
5,694,837
SC 13G/A
Feb 11, 2022
capital research global investors
9.7%
8,219,133
SC 13G/A

Recent SEC filings of Integra LifeSciences Holdings Corp

View All Filings
Date Filed Form Type Document
Nov 03, 2023
4
Insider Trading
Oct 25, 2023
8-K
Current Report
Oct 25, 2023
10-Q
Quarterly Report
Oct 13, 2023
4/A
Insider Trading
Sep 05, 2023
4
Insider Trading
Sep 05, 2023
3
Insider Trading

IART Fair Value

Loading...

Peers (Alternatives to Integra LifeSciences Holdings Corp)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.9B
40.0B
10.31% -2.25%
35.24
4.55
-11.26% -34.57%
71.3B
19.4B
-9.23% -5.96%
44.09
3.79
2.66% -16.58%
18.3B
15.0B
6.14% -30.83%
7.06
1.22
3.01% 209.09%
16.9B
3.8B
14.26% 16.16%
46.7
4.45
-1.48% -28.97%
MID-CAP
9.3B
12.7B
13.37% -11.57%
21
0.74
0.68% -30.25%
8.9B
2.7B
-0.34% -27.61%
-55.55
3.25
-3.01% 97.36%
8.4B
3.4B
1.77% 17.97%
29.76
2.43
3.13% 18.17%
6.8B
3.9B
15.17% 5.28%
-30.97
1.72
-2.62% 73.28%
2.9B
342.6M
7.33% -13.77%
-240.35
8.4
42.19% 84.14%
2.5B
6.6B
-12.19% -8.47%
12.51
0.38
2.61% 0.62%
SMALL-CAP
1.1B
3.1B
27.38% -62.38%
-2.62
0.36
7.95% -550.16%
328.7M
163.3M
8.29% -28.40%
-13.38
2.01
7.14% -56.09%
279.9M
335.9M
9.78% -43.73%
43.42
0.83
4.71% 116.39%
73.4M
50.3M
2.42% 10.99%
-4.85
1.46
3.23% 20.81%
5.0M
3.8M
4.66% -47.56%
-0.43
1.32
17.30% 10.67%

Integra LifeSciences Holdings Corp News

Latest updates
Nasdaq29 Nov 202303:00 pm10 days ago
Nasdaq28 Nov 202308:00 am11 days ago
Business Wire11 Nov 202302:00 am29 days ago
Stockhouse Publishing07 Nov 202308:00 am32 days ago
Stockhouse Publishing28 Sep 202307:00 am2 months ago
Business Wire13 Sep 202307:00 am2 months ago
24/7 Wall St.25 Aug 202307:00 am3 months ago
Mass Device23 Aug 202307:00 am3 months ago
Yahoo Finance10 Aug 202307:00 am4 months ago
GlobeNewswire16 Jul 202307:00 am4 months ago
Mass Device29 Jun 202307:00 am5 months ago
GlobeNewswire24 Jun 202307:00 am5 months ago
Mass Device22 Jun 202307:00 am5 months ago
GlobeNewswire09 Jun 202307:00 am6 months ago
The Motley Fool23 May 202307:00 am6 months ago

Financials for Integra LifeSciences Holdings Corp

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.3%382381381398385398377406387390360389370259354395379384360383366
Costs and Expenses-3.5%356369344330320338330347330338329336313245327359400338327349342
  S&GA Expenses-1.8%162165167152144161160162156163157162150116166174173165175177173
  R&D Expenses--------------15.0021.00-19.0018.0018.0020.0020.00
EBITDA Margin-19.2%0.11*0.13*0.16*0.17*0.16*0.15*0.15*0.17*0.17*0.17*0.24*0.20*0.19*0.13*0.14*------
Interest Expenses4.8%13.0012.0012.0013.0013.0012.0012.0012.0012.0013.0013.0017.0021.0016.0018.0013.0014.0013.0013.0014.0014.00
Income Taxes-146.7%-0.89-0.366.0011.009.007.006.006.008.0010.0022.00-53.839.002.002.0011.000.007.00-7.93-0.62-2.27
Earnings Before Taxes386.6%19.004.0030.0064.0059.0052.0039.0052.0051.0045.0067.0039.0042.002.0011.0026.00-27.5136.0025.0025.0011.00
EBT Margin-25.5%0.08*0.10*0.13*0.14*0.13*0.12*0.12*0.14*0.13*0.13*0.11*0.07*0.06*0.01*0.03*------
Net Income366.0%19.004.0024.0053.0050.0045.0033.0045.0043.0035.0045.0093.0032.00-0.379.0015.00-27.6130.0033.0025.0013.00
Net Income Margin-23.0%0.07*0.08*0.11*0.12*0.11*0.11*0.10*0.11*0.14*0.14*0.12*0.10*0.04*0.00*0.02*------
Free Cashflow7.5%14.0013.0012.0071.0059.0057.0035.0042.0075.0085.0062.0072.0063.0026.004.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-1.0%3,7393,7783,7423,8903,8073,7533,6723,7823,7743,7133,7423,6153,4543,3923,4483,3033,3473,2903,2063,1083,179
  Current Assets-2.3%1,0271,0511,0291,1611,1961,1371,0661,1541,1041,0321,0391,2371,1529661,009858884869823775828
    Cash Equivalents-11.5%274309307457512447407513470397409470396361358199208176157139206
  Inventory3.4%366354351325311320328317327324328310308359338316303297287280291
  Net PPE0.4%319318315311301302309312294296296288294334336337319316306300287
  Goodwill-0.7%1,0361,0431,0421,0399789901,0091,0131,01294.001,010932920956952954945927923926926
Liabilities3.1%2,1602,0942,0672,0852,0832,0922,0572,0982,1432,1382,2122,1002,0562,0432,1061,8871,9621,8691,8091,7321,814
  Current Liabilities-5.8%356377282321304296316340333319412401255212246331303315288263258
Shareholder's Equity-6.2%1,5791,6831,6751,8041,7241,6611,6151,6851,6321,5751,5291,5151,3981,3491,3421,4171,3851,4211,3971,3761,365
  Retained Earnings2.1%927908903879826776731699653610575532440407408399383411381348323
  Additional Paid-In Capital-1.7%1,2621,2841,2451,2771,2681,2601,2671,2651,2591,2491,2321,2911,2851,2791,2401,2141,2091,1981,1921,1931,188
Shares Outstanding-1.6%80.0081.0082.00-83.0083.0084.00-85.0085.0085.00-84.0085.0085.00-86.0086.0085.00-85.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-5.3%26,770,00028,279,00026,156,00085,334,00068,313,00066,478,00044,344,00069,277,00082,779,00091,290,00069,081,00080,262,00069,639,00033,117,00020,814,00089,184,00064,241,00048,524,00029,484,00042,688,00079,251,000
  Share Based Compensation3.6%5,459,0005,271,0003,620,0005,731,0008,967,0006,736,0006,291,0006,432,0007,745,00015,699,0006,334,0005,257,0005,411,0005,172,0003,750,0005,511,0005,885,0005,776,0004,083,0004,993,0005,572,000
Cashflow From Investing50.5%-7,697,000-15,548,000-13,704,000-54,820,00014,805,000-4,498,000-14,067,000-27,485,000-8,475,000-7,917,000-117,566,000-35,921,000-6,718,000-3,949,000-21,485,000-20,609,000-108,839,000-17,414,000-15,806,000-25,330,000-16,343,000
Cashflow From Financing-364.4%-49,659,000-10,693,000-162,683,000-97,699,000-7,642,000-13,147,000-133,465,000521,0001,743,000-97,475,000-3,015,00021,222,000-33,049,000-28,553,000162,005,000-81,992,00081,025,000-13,192,0005,393,000-84,055,000-39,839,000
  Buy Backs-126,249,000-151,200,000---125,000,000-----3,816,000-92,368,000------

IART Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Total revenue, net$ 382,421$ 385,191$ 1,144,534$ 1,159,644
Costs and expenses:    
Cost of goods sold164,076148,445486,292439,418
Research and development26,59624,73679,90874,410
Selling, general and administrative161,948143,820493,513464,397
Intangible asset amortization3,2083,1419,34210,339
Total costs and expenses355,828320,1421,069,055988,564
Operating income26,59365,04975,479171,080
Interest income4,6073,26412,6536,606
Interest expense(13,062)(12,809)(37,626)(36,700)
Gain (loss) from the sale of business06440644
Other income (expense), net4712,6481,7058,056
Income before income taxes18,60958,79652,211149,686
Provision (benefit) for income taxes(888)8,8814,30422,082
Net income$ 19,497$ 49,915$ 47,907$ 127,604
Net income per share    
Basic (in dollars per share)$ 0.24$ 0.60$ 0.59$ 1.54
Diluted (in dollars per share)$ 0.24$ 0.60$ 0.59$ 1.53
Weighted average common shares outstanding (See Note 13):    
Basic (in shares)79,69083,04280,84282,955
Diluted (in shares)79,81183,39981,11283,476
Comprehensive income (See Note 14)$ 16,412$ 55,691$ 39,387$ 165,320

IART Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 273,732$ 456,661
Trade accounts receivable, net of allowances of $5,630 and $4,304256,270263,465
Inventories, net366,251324,583
Prepaid expenses and other current assets130,976116,789
Total current assets1,027,2291,161,498
Property, plant and equipment, net318,718311,302
Right of use asset - operating leases156,760148,284
Intangible assets, net1,067,0231,126,609
Goodwill1,036,1461,038,881
Deferred tax assets, net55,58745,994
Other assets77,90857,190
Total assets3,739,3713,889,758
Current liabilities:  
Current portion of borrowings under senior credit facility9,68738,125
Current portion of borrowings under securitization facility75,7000
Current portion of lease liability - operating leases14,46114,624
Accounts payable, trade93,550102,100
Contract liabilities8,1397,253
Accrued compensation63,86978,771
Accrued expenses and other current liabilities90,30680,033
Total current liabilities355,712320,906
Long-term borrowings under senior credit facility850,089733,149
Long-term borrowings under securitization facility0104,700
Long-term convertible securities569,527567,341
Lease liability - operating leases168,017157,420
Deferred tax liabilities74,45363,338
Other liabilities142,352138,501
Total liabilities2,160,1502,085,355
Stockholders’ equity:  
Preferred stock; no par value; 15,000 authorized shares; none outstanding00
Common stock; $0.01 par value; 240,000 authorized shares; 90,935 and 90,477 issued at September 30, 2023 and December 31, 2022, respectively909905
Additional paid-in capital1,262,3191,276,977
Treasury stock, at cost; 11,823 shares and 6,823 shares at September 30, 2023 and December 31, 2022, respectively(612,777)(362,862)
Accumulated other comprehensive income1,74510,265
Retained earnings927,025879,118
Total stockholders’ equity1,579,2211,804,403
Total liabilities and stockholders’ equity$ 3,739,371$ 3,889,758
IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEwww.integralife.com
 EMPLOYEES3722

Integra LifeSciences Holdings Corp Frequently Asked Questions


What is the ticker symbol for Integra LifeSciences Holdings Corp? What does IART stand for in stocks?

IART is the stock ticker symbol of Integra LifeSciences Holdings Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Integra LifeSciences Holdings Corp (IART)?

As of Fri Dec 08 2023, market cap of Integra LifeSciences Holdings Corp is 3.29 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IART stock?

You can check IART's fair value in chart. The fair value of Integra LifeSciences Holdings Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Integra LifeSciences Holdings Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IART so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Integra LifeSciences Holdings Corp a good stock to buy?

The fair value guage provides a quick view whether IART is over valued or under valued. Whether Integra LifeSciences Holdings Corp is cheap or expensive depends on the assumptions which impact Integra LifeSciences Holdings Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IART.

What is Integra LifeSciences Holdings Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, IART's PE ratio (Price to Earnings) is 32.61 and Price to Sales (PS) ratio is 2.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IART PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Integra LifeSciences Holdings Corp's stock?

In the past 10 years, Integra LifeSciences Holdings Corp has provided 0.069 (multiply by 100 for percentage) rate of return.